Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 81 out of 100. Treatments

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Results A total of 985 and 980 participants were enrolled in the GRADUATE I and II trials, respectively. Conclusions Among persons with early Alzheimer's disease, the use of gantenerumab led to a lower amyloid plaque burden than placebo at 116 weeks but was not associated with slower clinical decline.

What this study adds

Evidence grade: Low

This is a trial of 980 participants. In two phase 3 trials, gantenerumab lowered amyloid plaque burden more than placebo at 116 weeks but was not associated with slower clinical decline. Reported effect size: 28.0%; 26.8%; 24.9%.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Bateman, R. J., Smith, J., Donohue, M. C., Delmar, P., Abbas, R., Salloway, S., et al. (2023). Two Phase 3 Trials of Gantenerumab in Early Alzheimer's Disease. The New England journal of medicine. https://doi.org/10.1056/nejmoa2304430

Vancouver

Bateman RJ, Smith J, Donohue MC, Delmar P, Abbas R, Salloway S, et al. Two Phase 3 Trials of Gantenerumab in Early Alzheimer's Disease. The New England journal of medicine. 2023. doi:10.1056/nejmoa2304430. PMID: 37966285.

BibTeX

@article{bateman2023-37966285,
  author  = {Bateman, R. J. and Smith, J. and Donohue, M. C. and Delmar, P. and Abbas, R. and Salloway, S. and Wojtowicz, J. and Blennow, K. and others},
  title   = {{Two Phase 3 Trials of Gantenerumab in Early Alzheimer's Disease}},
  journal = {The New England journal of medicine},
  year    = {2023},
  doi     = {10.1056/nejmoa2304430},
  pmid    = {37966285},
  url     = {https://doi.org/10.1056/nejmoa2304430}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

In two phase 3 trials, gantenerumab lowered amyloid plaque burden more than placebo at 116 weeks but was not associated with slower clinical decline. This means the drug did not slow the clinical course of early Alzheimer's disease.

Study details

How this study scored 81/100
How this study's score is builtJournal tier 10 of 10; Journal's citation record 4 of 4; Study design 11 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 3 of 5; Sample size 2 of 4; Effect reported 2 of 3; Studied in people 3 of 3; Randomized / blinded 1 of 2; Times cited 6 of 7; Citations per year 5 of 5; Impact for its field and year 6 of 6; Cited by studies here 3 of 6; Still being cited 4 of 4; Senior author's track record 3 of 4; Institution's track record 2 of 3; Multicenter collaboration 3 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. Total 81 of 100.81 of 100 points earned19 not earned

Published in a top-tier journal, and it is a large phase 3 trial.

ComponentPointsWhy
Journal tier 10 / 10 Tier 1 — top-tier general journal (The New England journal of medicine)
Journal's citation record 4 / 4 New England Journal of Medicine: journal h-index 1,505 (OpenAlex, 2026-10-29)
Study design 11 / 12 A large phase 3 trial (from PubMed type “Clinical Trial, Phase III”)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 3 / 5 2023 — within 6 year(s) of the newest study here
Sample size 2 / 4 980 participants
Effect reported 2 / 3 Effect reported as a number, without an interval or test
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 1 / 2 Randomized (as stated in the record)
Times cited 6 / 7 Cited 306 times (OpenAlex, 2026-10-10)
Citations per year 5 / 5 61.2 citations a year over 5 year(s) since 2023
Impact for its field and year 6 / 6 Cited 44.8× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 3 / 6 Cited by 29 other studies in this library
Still being cited 4 / 4 Cited 303 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 3 / 4 Last-listed author Rachelle Smith Doody: h-index 97 (OpenAlex, whole career)
Institution's track record 2 / 3 University College London: institution h-index 2,029 (OpenAlex)
Multicenter collaboration 3 / 3 OpenAlex lists 24 institution(s) in 9 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 37966285)
Free to read 0 / 2 Behind a paywall — scores zero
Total 81 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 19.

Later studies that cite this one

29 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.

Related studies in Treatments from nearby years

Also tagged “trial”

783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Treatments

See all studies in Treatments →